ReviewCardiology and therapy2022
Pulmonary Hypertension in the Population with Down Syndrome.
Review in Cardiology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Understanding Severe Sleep-Disordered Breathing in Down Syndrome: Insights from a Clinical-Polysomnographic Cohort.Journal of clinical medicine · 2026Article
- Impact of weight loss on cardiovascular function in adolescents and young adults with overweight/ obesity and intellectual and developmental disabilities.Disability and health journal · 2026Article
- Emerging role of DYRK1A as a target in cardiovascular diseases (Review).Molecular medicine reports · 2026Review
- Echocardiographic Assessment of Pulmonary Arterial Hypertension After Complete Atrioventricular Septal Defect Repair.Echocardiography (Mount Kisco, N.Y.) · 2026Article
- Predicted vs. Actual Endotracheal Tube Size in Pediatric Cardiac Surgery for Children with Down Syndrome.Annals of cardiac anaesthesia · 2026Article
- Eccentricity Index Is Associated With Pulmonary Arterial Hypertension in Children After Repair of Complete Atrioventricular Septal Defects.Echocardiography (Mount Kisco, N.Y.) · 2026Article
- Interferon receptor gene dosage differentially regulates hypoxia-induced platelet activation and pulmonary hypertension in down syndrome.Frontiers in immunology · 2026Article
- Gestational age-based outcomes of neonates with Down syndrome in the neonatal intensive care unit (NICU): review of pediatric health information system (PHIS) database.Journal of perinatology : official journal of the California Perinatal Association · 2025Article
- Cardiovascular complications in children with Down syndrome and sleep disordered breathing.Paediatric respiratory reviews · 2025Review
- Clinical and Immunological Impact of JAK Inhibition in Concurrent Down Syndrome and STAT1 Gain of Function.Journal of clinical immunology · 2025Article
- Cardiopulmonary and Immune Alterations in the Ts65Dn Mouse Model of Down Syndrome and Modulation by Epigallocatechin-3-Gallate-Enriched Green Tea Extract.Pharmaceutics · 2025Article
- Respiratory and airway disorders in children with Down Syndrome: a review of the clinical challenges and management.Frontiers in pediatrics · 2025Review
- Anaesthesia for the child with trisomy 21.BJA education · 2024Review
- Down syndrome and postoperative hemodynamics in patients undergoing surgery for congenital cardiac communications.Scientific reports · 2024Article
- A French nationwide study compared various conditions and healthcare use of individuals < 65 years with a Down's syndrome to those without.Scientific reports · 2023Article
- RUN(X) out of blood: emerging RUNX1 functions beyond hematopoiesis and links to Down syndrome.Human genomics · 2023Review
- Long-Term Non-Congenital Cardiac and Renal Complications in Down Syndrome: A Study of 32,936 Patients.Children (Basel, Switzerland) · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persons with Down syndrome (DS) have an increased reported incidence of pulmonary hypertension (PH). A majority of those with PH have associations with congenital heart disease (CHD) or persistent pulmonary hypertension of the newborn (PPHN); however, there are likely multifactorial contributions that include respiratory comorbidities. PH appears to be most commonly identified early in life, although respiratory challenges may contribute to a later diagnosis or even a recurrence of previously resolved PH in this population. Currently there are few large-scale, prospective, lifetime cohort studies detailing the impact PH has on the population with DS. This review will attempt to summarize the epidemiology and characteristics of PH in this population. This article will additionally review current known and probable risk factors for developing PH, review pathophysiologic mechanisms of disease in the population with DS, and evaluate current screening and management recommendations while suggesting areas for additional or ongoing clinical, translational, and basic science research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.